Danaher (DHR) Expected to Announce Earnings on Tuesday

Danaher (NYSE:DHR) is expected to post its quarterly earnings results before the market opens on Tuesday, April 22nd. Analysts expect Danaher to post earnings of $1.62 per share and revenue of $5.58 billion for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Stock Performance

NYSE:DHR opened at $193.02 on Tuesday. The stock has a 50 day simple moving average of $203.33 and a 200 day simple moving average of $229.00. The stock has a market cap of $137.95 billion, a P/E ratio of 36.56, a PEG ratio of 2.66 and a beta of 0.86. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.66%. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Robert W. Baird decreased their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. JPMorgan Chase & Co. lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company dropped their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Guggenheim started coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Finally, The Goldman Sachs Group raised Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price objective for the company in a report on Friday, March 21st. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $276.57.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.